Bio Essence Corp (BIOE)

AI-Powered SEC Filing Analysis

Quarterly Report Filed: 2026-05-15

Key Insights

Revenue surged to $500.5K in Q1 2026 from $22.2K in Q1 2025, a 22.5x increase driven by OEM services, demonstrating significant business traction and potential market validation.
Company achieved profitability with $205.4K net income in Q1 2026 versus a $205.8K net loss in Q1 2025, representing a substantial $411.2K swing that marks a critical inflection point.
Stockholders' deficit improved significantly from $2.07M to $1.43M through a combination of profitability and $440K in equity financing (8.8M new shares issued), though the company remains technically insolvent.
Operating lease liabilities of $1.51M represent 68% of total current liabilities and pose a material cash flow risk; combined with negative operating cash flow of $411.9K in Q1, the company faces near-term liquidity pressure.
Customer deposits decreased from $848.6K to $611.1K, suggesting either fulfillment of prior orders or customer cancellations, which warrants clarification regarding revenue sustainability and customer concentration.

Current Report Filed: 2026-04-24

Key Insights

Bio Essence acquired MediFlow AI (formerly AcuVital) software from Zhituo Software for $3.5 million in common stock, representing a significant asset addition to the company's product portfolio in healthcare AI technology.
The acquisition involves issuance of common stock valued at $3.5 million, which requires Board approval for final share count determination, creating potential dilution to existing shareholders depending on current stock valuation.
No prior material relationship existed between Bio Essence and Zhituo, suggesting this is a new strategic acquisition rather than an internal transaction, with the software's full technical specifications (source code, architecture, data, frameworks) transferred to the company.
The company is classified as an emerging growth company, indicating it is early-stage and may face higher execution risks in integrating and commercializing the acquired AI software asset.

Annual Report Filed: 2026-03-27

Key Insights

Bio Essence Corp is a smaller reporting company, which suggests it may have lower liquidity and less financial information available to investors.
The company is not required to file reports with the SEC, potentially limiting transparency for shareholders.
Bio Essence Corp had an aggregate market value of its common stock held by non-affiliates of $26.8 million as of December 31, 2025, indicating a relatively small market capitalization.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.